Victory Capital Management
NKTR icon

Victory Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Victory Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$225K Buy
+3,127
New +$178K ﹤0.01% 2180
2025
Q3 		– Sell
-14,137
Closed -$365K – 2502
2025
Q2 		$365K Buy
14,137
+12,708
+889% +$143K ﹤0.01% 2111
2025
Q1 		$14.6K Sell
1,429
-41
-3% -$536 ﹤0.01% 2445
2024
Q4 		$20.5K Sell
1,470
-34
-2% -$600 ﹤0.01% 2439
2024
Q3 		$29.3K Sell
1,504
-31
-2% -$591 ﹤0.01% 2424
2024
Q2 		$28.6K Buy
+1,535
New +$32.4K ﹤0.01% 2404
2023
Q4 		– Sell
-1,365
Closed -$12.2K – 2603
2023
Q3 		$12.2K Buy
1,365
+34
+3% +$327 ﹤0.01% 2476
2023
Q2 		$11.5K Sell
1,331
-809
-38% -$8.63K ﹤0.01% 2481
2023
Q1 		$22.6K Sell
2,140
-566
-21% -$17.1K ﹤0.01% 2502
2022
Q4 		$91.7K Hold
2,706
– – ﹤0.01% 2374
2022
Q3 		$130K Buy
2,706
+361
+15% +$21.5K ﹤0.01% 2434
2022
Q2 		$134K Buy
2,345
+86
+4% +$5.43K ﹤0.01% 2418
2022
Q1 		$140K Buy
2,259
+1,257
+125% +$186K ﹤0.01% 2468
2021
Q4 		$203K Sell
1,002
-9
-0.9% -$1.95K ﹤0.01% 2480
2021
Q3 		$272K Sell
1,011
-4
-0.4% -$962 ﹤0.01% 2414
2021
Q2 		$261K Sell
1,015
-11
-1% -$3.04K ﹤0.01% 2461
2021
Q1 		$308K Buy
1,026
+4
+0.4% +$1.25K ﹤0.01% 2385
2020
Q4 		$261K Buy
1,022
+55
+6% +$14.2K ﹤0.01% 2324
2020
Q3 		$241K Sell
967
-31
-3% -$9.75K ﹤0.01% 2239
2020
Q2 		$347K Sell
998
-5,200
-84% -$1.62M ﹤0.01% 2118
2020
Q1 		$1.66M Buy
6,198
+4,708
+316% +$1.46M ﹤0.01% 1666
2019
Q4 		$482K Buy
1,490
+1,344
+921% +$390K ﹤0.01% 2032
2019
Q3 		$40K Sell
146
-21
-13% -$7.7K ﹤0.01% 2779
2019
Q2 		$89K Sell
167
-3
-2% -$1.5K ﹤0.01% 1651
2019
Q1 		$86K Hold
170
– – ﹤0.01% 1669
2018
Q4 		$84K Sell
170
-1
-0.6% -$604 ﹤0.01% 1654
2018
Q3 		$156K Sell
171
-26
-13% -$22.2K ﹤0.01% 1624
2018
Q2 		$144K Sell
197
-35
-15% -$40.4K ﹤0.01% 1670
2018
Q1 		$369K Buy
232
+137
+144% +$177K ﹤0.01% 1405
2017
Q4 		$85K Sell
95
-132
-58% -$78.1K ﹤0.01% 1712
2017
Q3 		$82K Hold
227
– – ﹤0.01% 1713
2017
Q2 		$67K Buy
227
+4
+2% +$1.16K ﹤0.01% 1716
2017
Q1 		$79K Buy
223
+29
+15% +$6.52K ﹤0.01% 1689
2016
Q4 		$36K Buy
194
+11
+6% +$2.24K ﹤0.01% 1731
2016
Q3 		$47K Buy
183
+12
+7% +$3.09K ﹤0.01% 1714
2016
Q2 		$36K Buy
171
+4
+2% +$894 ﹤0.01% 1566
2016
Q1 		$35K Buy
167
+12
+8% +$2.31K ﹤0.01% 1525
2015
Q4 		$39K Buy
155
+15
+11% +$3.08K ﹤0.01% 1596
2015
Q3 		$23K Buy
+140
New +$24.8K ﹤0.01% 1577

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Victory Capital Management's NKTR Position: Q1 2026 in Review

Victory Capital Management opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 3,127 shares worth $225K. The stake represents ﹤0.01% of the portfolio and ranks #2180 among its holdings. This is a return to the name: Victory Capital Management previously reported a position in NKTR as recently as Q2 2025.

Victory Capital Management first reported a position in NKTR in Q3 2015 and has held it in 39 quarters since. The position peaked at $1.66M in Q1 2020. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Victory Capital Management held 3,127 shares of Nektar Therapeutics worth $225K as of Q1 2026.
  • Nektar Therapeutics was a new Victory Capital Management position in Q1 2026.
  • Nektar Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #2180 holding.
  • Victory Capital Management first reported a position in Nektar Therapeutics in Q3 2015 and has held it in 39 quarters since.
  • Victory Capital Management's Nektar Therapeutics position peaked at $1.66M in Q1 2020.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.